Work

Abstract P5-21-12: Tolerability of olaparib monotherapy versus chemotherapy in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD

Year: 2018

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.sabcs17-p5-21-12

Authors: SM Domchek, M Robson, S-A Im, E Senkus, B Xu, N Masuda, S Delaloge, W Li, A Armstrong, P Conte, W Bannister, C Goessl, S Runswick, S Goel, N Tung

Institutions: Beth Israel Deaconess Medical Center, Memorial Sloan Kettering Cancer Center, University of Padua, Jilin University, Chinese Academy of Medical Sciences & Peking Union Medical College, Institut Gustave Roussy, Seoul National University Hospital, University of Manchester, Gdańsk Medical University, University of Pennsylvania

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2790413194

Cites:

Cited by: 3

Related to: 10